CO6270338A2 - Composiciones para provocar una respuesta inmune contra mycobacterium avium subspecies paratuberculosis - Google Patents
Composiciones para provocar una respuesta inmune contra mycobacterium avium subspecies paratuberculosisInfo
- Publication number
- CO6270338A2 CO6270338A2 CO10057537A CO10057537A CO6270338A2 CO 6270338 A2 CO6270338 A2 CO 6270338A2 CO 10057537 A CO10057537 A CO 10057537A CO 10057537 A CO10057537 A CO 10057537A CO 6270338 A2 CO6270338 A2 CO 6270338A2
- Authority
- CO
- Colombia
- Prior art keywords
- map
- compositions
- protein
- kda
- infection
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invencion proporciona composiciones y métodos para estimular una respuesta inmunologica en mamiferos contra MAP. Las composiciones comprenden un novedoso polipéptidos recombinante de 79 kDa, designado en esta especificacion como "Map74F". Map74F se genero conectando un fragmento C-terminal de ~17,6 kDa de la proteina Map3527 a un fragmento de la proteina Map519, seguido en el término C por una porcion N-terminal de 14.6 kDa de la proteina Map3527.Ademas del Map74F, las composiciones de la invencion pueden comprender asi mismo otras proteinas MAP, tales como las proteinas MAP 85A, 85B, 85C, 35kDa, SOD, MptC, MptD y la proteina con caracteristicas similares a ESAT-6 ("ESAT-6 like protein"), y combinaciones de las mismas.El método comprende administrar la composicion a un mamifero en una cantidad efectiva para estimular una respuesta inmunologica contra bacterias MAP, Se espera que el método sea beneficioso a cualquier mamifero susceptible a infeccion con MAP, pero es particularmente benéfico para rumiantes.Las composiciones pueden formularse con vehiculos farmacéuticos estandar y pueden administrarse mediante cualquiera de una variedad de vias convencionales. Las composiciones pueden administrarse en cualquier momento a un animal susceptible de contraer la infeccion con MAP o a un animal que esta infectado con MAP. No obstante, es preferible administrar las composiciones antes de la infeccion con MAP, tal como mediante administracion a animales pre±ados que pueden transmitir componentes inmunologicos profilacticos a sus recién nacidos a través del calostro, o mediante administracion durante el periodo de una a cinco semanas después del parto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97982207P | 2007-10-13 | 2007-10-13 | |
| US9455208P | 2008-09-05 | 2008-09-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6270338A2 true CO6270338A2 (es) | 2011-04-20 |
Family
ID=40534814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10057537A CO6270338A2 (es) | 2007-10-13 | 2010-05-13 | Composiciones para provocar una respuesta inmune contra mycobacterium avium subspecies paratuberculosis |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7732580B2 (es) |
| EP (1) | EP2200641B1 (es) |
| JP (1) | JP2011500587A (es) |
| KR (1) | KR20100098602A (es) |
| CN (1) | CN101883582B (es) |
| AU (1) | AU2008310767A1 (es) |
| BR (1) | BRPI0817892A2 (es) |
| CA (1) | CA2704178A1 (es) |
| CO (1) | CO6270338A2 (es) |
| ES (1) | ES2390996T3 (es) |
| IN (1) | IN2010DN02553A (es) |
| MX (1) | MX2010003972A (es) |
| NZ (1) | NZ584659A (es) |
| PL (1) | PL2200641T3 (es) |
| PT (1) | PT2200641E (es) |
| RU (1) | RU2489165C2 (es) |
| WO (1) | WO2009049097A1 (es) |
| ZA (1) | ZA201002553B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013151706A2 (en) | 2012-04-06 | 2013-10-10 | Cornell University | Subunit vaccine delivery platform for robust humoral and cellular immune responses |
| US9175049B2 (en) | 2012-10-24 | 2015-11-03 | The United States Of America, As Represented By The Secretary Of Agriculture | Recombinant mycobacterium avium subsp. paratuberculosis proteins induce immunity and protect against infection |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5322858A (en) * | 1992-02-14 | 1994-06-21 | Jacobus Pharmaceutical Co. Inc. | N,N'-substituted imidodicarbonimidic diamides derived from hydroxylamines |
| KR100797876B1 (ko) * | 1998-04-07 | 2008-01-24 | 코릭사 코포레이션 | 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도 |
| WO2001098460A2 (en) * | 2000-06-20 | 2001-12-27 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
| US7074559B2 (en) * | 2002-03-06 | 2006-07-11 | Refents of the University of Minnesota | Mycobacterial diagnostics |
| ES2357968T3 (es) * | 2005-02-16 | 2011-05-04 | Cornell Research Foundation, Inc. | Composiciones para desencadenar una respuesta inmunitaria contra mycobacterium avium subespecie paratuberculosis. |
| US8758773B2 (en) | 2005-12-09 | 2014-06-24 | Wisconsin Alumni Research Foundation | Vaccine candidates against Johne's disease |
-
2008
- 2008-10-09 KR KR1020107010437A patent/KR20100098602A/ko not_active Application Discontinuation
- 2008-10-09 ES ES08837410T patent/ES2390996T3/es active Active
- 2008-10-09 MX MX2010003972A patent/MX2010003972A/es not_active Application Discontinuation
- 2008-10-09 WO PCT/US2008/079425 patent/WO2009049097A1/en active Application Filing
- 2008-10-09 RU RU2010119046/15A patent/RU2489165C2/ru not_active IP Right Cessation
- 2008-10-09 PL PL08837410T patent/PL2200641T3/pl unknown
- 2008-10-09 PT PT08837410T patent/PT2200641E/pt unknown
- 2008-10-09 EP EP08837410A patent/EP2200641B1/en active Active
- 2008-10-09 BR BRPI0817892 patent/BRPI0817892A2/pt not_active IP Right Cessation
- 2008-10-09 CA CA2704178A patent/CA2704178A1/en not_active Abandoned
- 2008-10-09 AU AU2008310767A patent/AU2008310767A1/en not_active Abandoned
- 2008-10-09 JP JP2010529059A patent/JP2011500587A/ja not_active Ceased
- 2008-10-09 CN CN200880119048.7A patent/CN101883582B/zh not_active Expired - Fee Related
- 2008-10-09 NZ NZ584659A patent/NZ584659A/en not_active IP Right Cessation
- 2008-10-09 US US12/248,764 patent/US7732580B2/en not_active Expired - Fee Related
-
2010
- 2010-04-12 ZA ZA2010/02553A patent/ZA201002553B/en unknown
- 2010-04-13 IN IN2553DEN2010 patent/IN2010DN02553A/en unknown
- 2010-05-13 CO CO10057537A patent/CO6270338A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2200641A4 (en) | 2010-09-29 |
| IN2010DN02553A (es) | 2015-07-24 |
| RU2010119046A (ru) | 2011-11-20 |
| NZ584659A (en) | 2011-09-30 |
| WO2009049097A1 (en) | 2009-04-16 |
| MX2010003972A (es) | 2010-08-09 |
| KR20100098602A (ko) | 2010-09-08 |
| CA2704178A1 (en) | 2009-04-16 |
| PL2200641T3 (pl) | 2012-12-31 |
| ES2390996T3 (es) | 2012-11-20 |
| JP2011500587A (ja) | 2011-01-06 |
| RU2489165C2 (ru) | 2013-08-10 |
| BRPI0817892A2 (pt) | 2015-05-05 |
| AU2008310767A1 (en) | 2009-04-16 |
| EP2200641B1 (en) | 2012-07-04 |
| US20090099083A1 (en) | 2009-04-16 |
| EP2200641A1 (en) | 2010-06-30 |
| CN101883582A (zh) | 2010-11-10 |
| CN101883582B (zh) | 2014-03-19 |
| US7732580B2 (en) | 2010-06-08 |
| ZA201002553B (en) | 2010-12-29 |
| PT2200641E (pt) | 2012-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rosa et al. | Lactoferrin: a natural glycoprotein involved in iron and inflammatory homeostasis | |
| Kuhara et al. | Oral administration of lactoferrin increases NK cell activity in mice via increased production of IL-18 and type I IFN in the small intestine | |
| Schülke et al. | A fusion protein of flagellin and ovalbumin suppresses the TH2 response and prevents murine intestinal allergy | |
| ES2738658T3 (es) | Composición farmacéutica para inhibir la respuesta inmunitaria a través de la inducción de la diferenciación en células T reguladoras y la promoción de la proliferación de células T reguladoras | |
| EA201490393A1 (ru) | Соматотропный гормон пролонгированного действия и способы его получения | |
| Jiang et al. | Comparison of bioactivities of talactoferrin and lactoferrins from human and bovine milk | |
| BR112015018411A2 (pt) | composições nutritivas contendo uma fração lipídica enriquecida e usos destas | |
| ECSP12012022A (es) | Formula nutricional que comprende un péptido de leche de vaca que contiene hidrolizado y/o péptidos derivados del mismo para la inducción de tolerancia | |
| BR112012018951C8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
| AR106624A1 (es) | Composiciones nutricionales que contienen butirato dietario y usos de las mismas | |
| WO2017096327A3 (en) | Compositions and methods for reducing immune responses against chimeric antigen receptors | |
| BR112014009225A8 (pt) | uso de micelas de proteína de soro de leite para crianças pequenas em risco de obesidade ou diabetes | |
| Puth et al. | Mucosal immunization with a flagellin-adjuvanted Hgp44 vaccine enhances protective immune responses in a murine Porphyromonas gingivalis infection model | |
| WO2007147011A3 (en) | Polynucleotide therapy | |
| AR077611A1 (es) | Metodo y conjunto de elementos ( kit) para tratar la adiccion a la nicotina. combinacion. uso. | |
| PE20142082A1 (es) | Composiciones nutricionales de caseina - suero de leche parcialmente hidrolizadas para reducir la aparicion de alergias | |
| CO6270338A2 (es) | Composiciones para provocar una respuesta inmune contra mycobacterium avium subspecies paratuberculosis | |
| WO2012091946A3 (en) | Method for inhibiting pathogens using a nutritional composition | |
| Arjunan | Eye on the enigmatic link: dysbiotic oral pathogens in ocular diseases; the flip side | |
| BR112015027636A2 (pt) | Uso da composição farmacêutica | |
| Nadolska et al. | Lactoferrin inhibits the growth of nasal polyp fibroblasts | |
| Pirestani et al. | Effects of dietary L-carnitine and choline chloride compound on reproduction indices and udder immune system in Holstein dairy cattle | |
| BR112021019979A2 (pt) | Tratamento envolvendo interleucina-2 (il2) e interferon (ifn) | |
| EA201370155A1 (ru) | Композиция и способ лечения рака | |
| MX2022013868A (es) | Composicion para utilizarse en el fortalecimiento del sistema inmunitario en seres humanos y animales para adquirir paninmunidad. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |